Creekmur Asset Management LLC Has $627,000 Stake in Novo Nordisk A/S (NYSE:NVO)

Creekmur Asset Management LLC grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 784.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,031 shares of the company’s stock after purchasing an additional 8,010 shares during the period. Creekmur Asset Management LLC’s holdings in Novo Nordisk A/S were worth $627,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Strategic Investment Solutions Inc. IL increased its holdings in shares of Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock valued at $27,000 after purchasing an additional 300 shares during the period. Copeland Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. acquired a new position in Novo Nordisk A/S in the first quarter worth approximately $27,000. Park Square Financial Group LLC acquired a new position in Novo Nordisk A/S in the fourth quarter worth approximately $29,000. Finally, Transce3nd LLC acquired a new position in Novo Nordisk A/S in the fourth quarter worth approximately $33,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on NVO. Dbs Bank downgraded Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. BMO Capital Markets reaffirmed a “market perform” rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Hsbc Global Res raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, April 28th. BNP Paribas started coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an “underperform” rating for the company. Finally, Wall Street Zen raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Saturday, June 14th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $112.00.

Novo Nordisk A/S Stock Down 0.4%

NVO opened at $65.02 on Friday. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $139.74. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $290.31 billion, a price-to-earnings ratio of 19.27, a P/E/G ratio of 1.29 and a beta of 0.64. The business has a 50 day moving average of $70.37 and a 200-day moving average of $74.53.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. The firm had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.